8-OHdG in cerebrospinal fluid as a marker of oxidative stress in various neurodegenerative diseases

Neurodegenerative Diseases

Volumn 6, Issue 5-6, 2009, Pages 263-269

  Gmitterova, K ^a,b   Heinemann, U ^a   Gawinecka, J ^a   Varges, D ^a   Ciesielczyk, B ^a   Valkovic, P ^b   Benetin, J ^b   Zerr, I ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b Physics and Informatics   (Slovakia)

Author keywords

8 OHdG; Cerebrospinal fluid; Oxidative stress; Parkinson's disease

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; BIOLOGICAL MARKER;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID; CONTROLLED STUDY; DIFFUSE LEWY BODY DISEASE; DISEASE MARKER; DNA DEGRADATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; MAJOR CLINICAL STUDY; NEUROCHEMISTRY; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL;

AGED; AGED, 80 AND OVER; DEOXYGUANOSINE; FEMALE; HUMANS; MALE; MENTAL STATUS SCHEDULE; MIDDLE AGED; NEURODEGENERATIVE DISEASES; OXIDATIVE STRESS; RETROSPECTIVE STUDIES;

EID: 77949423969     PISSN: 16602854     EISSN: 16602862     Source Type: Journal    
DOI: 10.1159/000237221     Document Type: Article

References (41)

1. Ferrante RJ, Browne SE, Shinobu LA, Bowling AC, Baik MJ, MacGarvey U, Kowall NW, Brown RHJ, Beal MF: Evidence of increased oxidative damage in both sporadic and familial amyotrophic lateral sclerosis. J Neurochem 1997; 69: 2064-2074.
2. Bogdanov M, Brown RH, Matson W, Smart R, Hayden D, O'Donnell H, Beal MF, Cudkowicz M: Increased oxidative damage to DNA in ALS patients. Free Rad Biol Med 2000; 29: 652-658.
3. Browne SE, Bowling AC, MacGarvey U, Baik MJ, Berger SC, Muqit MM, Bird ED, Beal MF: Oxidative damage and metabolic dysfunction in Huntington's disease: selective vulnerability of the basal ganglia. Ann Neurol 1997; 41: 646-653.
4. Kikuchi A, Takeda A, Onodera H, Kimpara T, Hisanaga K, Sato N, Nunomura A, Castellani RJ, Perry G, Smith MA, Itoyama Y: Systemic increase of oxidative nucleic acid damage in Parkinson's disease and multiple system atrophy. Neurobiol Dis 2002; 9: 244-248.
5. Sanchez-Ramos JR, Overvik E, Ames BN: A marker of oxyradical-mediated DNA damage (8-hydroxy-2-deoxyguanosine) is increased in nigra-striatum of Parkinson's disease brain. Neurodegeneration 1994; 3: 197-204.
6. Mecocci P, MacGarvey U, Beal F: Oxidative damage to mitochondrial DNA is increased in Alzheimer's disease. Ann Neurol 1994; 36: 747-751.
7. Nunomura A, Perry G, Alieu G, Hirai K, Takedu A, Balraj EK, Jones PK, Ghanbari H, Wataya T, Shimohama S, Chiba S, Atwood CS, Petersen RB, Smith MA: Oxidative damage is the earliest event in Alzheimer disease. J Neuropathol Exp Neurol 2001; 60: 759-767.
8. Lovell MA, Markesbery WR: Ratio of 8-Hydroxyguanine in intact DNA to free 8-hydroxyguanine is increased in Alzheimer disease ventricular cerebrospinal fluid. Arch Neurol 2001; 58: 392-396.
9. Adelman R, Saul RL, Ames BN: Oxidative damage to DNA: relation to species metabolic rate and life span. Proc Natl Acad Sci USA 1988; 85: 2706-2708.
10. Fiala ES, Conaway CC, Mathis JE: Oxidative DNA and RNA damage in the livers of Sprague-Dawley rats treated with the hepatocarcinogen 2-nitropropane. Cancer Res 1989; 49: 5518-5522.
11. Wamer WG, Wei RR: In vitro photooxidation of nucleic acids by ultraviolet A radiation. Photochem Photobiol 1997; 65: 506-563.
12. Hofer T, Badouard C, Bajak E, Ravanat JL, Mattsson A, Cotgreave IA: Hydrogen peroxide causes greater oxidation in cellular RNA than in DNA. Biol Chem 2005; 386: 333-337.
13. Christen Y: Oxidative stress and Alzheimer disease. Am J Clin Nutr 2000; 71: 6215-6295.
14. Beal MF, Lang AE, Ludolph A: Neurodegenerative Diseases. Cambridge, Cambridge University Press, 2005.
15. Lin MT, Beal MF: Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 2006; 443: 787-795.
16. Mecocci P, MacGarvey U, Kaufmann AE: Oxidative damage to mitochondrial DNA shows marked age-dependent increases in human brain. Ann Neurol 1993; 34: 609-616.
17. Gabbita SP, Lovell MA, Markesbery WR: Increased nuclear DNA oxidation in the brain in Alzheimer's disease. J Neurochem 1998; 71: 2034-2040.
18. Alam ZI, Jenner A, Daniel SE, Lees AJ, Cairns N, Marsden CD, Jenner P, Halliwell B: Oxidative DNA damage in the parkinsonian brain: an apparent selective increase in 8-hydroxyguanine levels in substantia nigra. J Neurochem 1997; 69: 1196-1203.
19. Zhang J, Perry G, Smith MA, Robertson D, Olson SJ, Graham DG, Montine TJ: Parkinson's disease is associated with oxidative damage to cytoplasmic DNA and RNA in substantia nigra neurons. Am J Pathol 1999; 154: 1423-1429.
20. Mecocci P, Polidori MC, Ingegni T, Cherubini A, Chionne F, Cecchetti R, Senin U: Oxidative damage to DNA in lymphocytes from AD patients. Neurology 1998; 51: 1014-1017.
21. Jenner P, Dexter DT, Sian J, Schapira AH, Marsden CD: Oxidative stress as a cause of nigral cell death in Parkinson's disease and incidental Lewy body disease: The Royal Kings and Queens Parkinson's Disease Research Group. Ann Neurol 1992; 32:S82-S87.
22. Nunomura A, Chiba S, Kosaka K: Neuronal RNA oxidation is a prominent feature of dementia with Lewy bodies. Neuroreport 2002; 13: 2035-2039.
23. Guentchev M, Siedlak SL, Jarlus C, Tagliavini F, Castellani RJ, Perry G, Smith MA, Budka H: Oxidative damage to nucleic acids in human prion disease. Neurobiol Dis 2002; 9: 275-281.
24. Hayashi M, Arai N, Satoh J: Neurodegenerative mechanisms in subacute sclerosing panencephalitis. J Child Neurol 2002; 17: 725-1281
25. Shan X, Lin CLG: Quantification of oxidized RNAs in Alzheimer's disease. Neurobiol Aging 2006; 27: 657-662.
26. Honda K, Smith MA, Zhu X, Baus D, Merrick WC, Tartakoff AM, Hattier T, Harris PL, Siedlak SL, Fujioka H, Liu Q, Moreira PI, Miller FP, Nunomura A, Shimohama S, Perry G: Ribosomal RNA in Alzheimer disease is oxidized by bound redox-active iron. J Biol Chem 2005; 280: 20978-20986.
27. Abe T, Isobe C, Murata T, Sato C, Tohgi H: Alteration of 8-hydroxyguanosine concentrations in the cerebrospinal fluid and serum from patients with Parkinson's disease. Neurosci Lett 2003; 336: 105-108.
28. McKhann G, Drachmann D, Folstein M, Katzmann R, Price D, Stadlan EM: Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of the Department of Health and Human Services Task Force of Alzheimer's disease. Neurology 1984; 34: 934-944.
29. McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen LA, Salmon DP, Lowe J, Mirra SS, Byrne EJ, Lennox G, Quinn NP, Edwardson JA, Ince PG, Bergeron C, Burns A, Miller BL, Lovestone S, Collerton D, Jansen EN, Ballard C, de Vos RA, Wilcock GK, Jellinger KA, Perry RH: Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 1996; 47: 1113-1124.
30. Huges AJ, Daniel SE, Blankson S, Lees AJ: A clinicopathologic study of 100 cases of Parkinson's disease. Arch Neurol 1993; 50: 140-148.
31. Emre M, Aarsland D, Brown R, Burn DJ, Duyckaerts C, Mizuno Y, Broe GA, Cummings J, Dickson D, Gauthier S, Goldman J, Goetz C, Korczyn A, Lees A, Levy R, Litvan I, McKeith IG, Olanow W, Poewe W, Quinn N, Sampaio C, Tolosa E, Dubois B: Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord 2007; 22: 1689-1707.
32. Praticò D, Reilly M, Lawson JA, FitzGerald GA: Novel indices of oxidant stress in cardiovascular disease: specific analysis of F2- isoprostanes. Agents Actions Suppl 1997; 48: 25-41.
33. Sabbagh MN, Silverberg N, Bircea S, Majeed B, Samant S, Caviness JN, Reisberg B, Adler CH: Is the functional decline of Parkinson's disease similar to the functional decline of Alzheimer's disease? Parkinsonism Relat Disord 2005; 11: 311-315.
34. Braak H, Rüb U, Jansen Steur EN, Del Tredici K, de Vos RA: Cognitive status correlates with neuropathologic stage in Parkinson disease. Neurology 2005; 64: 1404-1410.
35. Braak H, Rüb U, Del Tredici K: Cognitive status correlates with neuropathologic stage in Parkinson's disease. J Neurol Sci 2006; 248: 255-258.
36. Bogdanov M, Matson WR, Wang L, Matson T, Saunders-Pullmann S, Bressman SS, Beal F: Metabolomic profiling to develop blood biomarkers for Parkinson's disease. Brain 2008; 131: 389-396.
37. Blin O, Desnuelle C, Rascol O, Borg M, Peyro Saint Paul H, Azulay JP, Bille F, Figarella D, Coulom F, Pellissier JF, Montastruc JL, Chatel M, Serratrice G: Mitochondrial respiratory failure in skeletal muscle from patients with Parkinson's disease and multiple system atrophy. J Neurol Sci 1994; 125: 95-101.
38. Barroso N, Campos Y, Huertas R, Esteban J, Molina JA, Alonso A, Gutierrez-Rivas E, Arenas J: Respiratory chain enzyme activities in lymphocytes from untreated patients with Parkinson disease. Clin Chem 1993; 39: 667-669.
39. Wakabayashi K, Takahashi H, Ohama E, Takeda S, Ikuta F: Lewy bodies in the visceral autonomic nervous system in Parkinson's disease. Adv Neurol 1993; 60: 609-612.
40. Zhang R, Pinson A, Samuni A: Both hydroxylamine and nitroxide protect cardiomyocytes from oxidative stress. Free Rad Biol Med 1998; 24: 66-75.
41. Nunomura A, Perry G, Pappolla MA: RNA oxidation is a prominent feature of vulnerable neurons in Alzheimer's disease. J Neurosci 1999; 19: 1959-1964.